Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): A study of 8 years of follow-up

Documenta Ophthalmologica

Volumn 110, Issue 1, 2005, Pages 91-102

  Parisi, Vincenzo ^a  

^a Fondazione Oftalmologia GB Bietti   (Italy)

Author keywords

Citicoline; Glaucoma; Innermost retinal layers; Pattern electroretinogram; Visual evoked potentials; Visual function; Visual pathways

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEBROTON; CITICOLINE; NEUROTON; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; FOLLOW UP; HUMAN; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISION; VISUAL IMPAIRMENT;

CYTIDINE DIPHOSPHATE CHOLINE; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; MIDDLE AGED; NOOTROPIC AGENTS; PHOTIC STIMULATION; RETINA; TIME FACTORS; TREATMENT OUTCOME;

EID: 30344451395     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10633-005-7348-7     Document Type: Article

References (73)

1. Krieglstein GK, Screms W, Leydhecker W Detectability of early glaucomatous field defects. A controlled comparison of Goldmann versus Octopus perimetry. Doc Ophthalmol Proc Ser 1980; 26: 19-24.
2. Werner EB, Piltz-Seymour J. What constitutes a glaucomatous visual field defects. Semin Ophthalmol 1992; 7: 110-9.
3. Gunduz K, Arden GB, Perry S, Weinstein GW, Hitchings RA. Colour vision defects in ocular hypertension and glaucoma. Quantification with a computer driven colour television system. Arch Ophthal 1988; 106: 929-35. 3260483
4. Arden GB, Jacobson JJ. A simple grating test of contrast sensitivity. Preliminary results indicate value in screening for glaucoma. Invest Ophthalmol Vis Sci 1978; 17: 23-32. 621124
5. Hitchings RA, Powell DJ, Arden GB, Carter RM. Contrast sensitivity gratings in glaucoma family screening. Br J Ophthalmol 1981; 61: 107-13.
6. Pomerance GN, Evans DW. Test-retest reliability of the CVS1000 contrast test and its relationship to glaucoma therapy. Invest Ophtahlmol Vis Sci 1994; 35: 3357-61.
7. Pecori Giraldi J, Virno M, Covelli G, Grechi G, De Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma (Computerized and automatic perimetric investigation). Int Ophthalmol 1989; 13: 109-15. 10.1007/BF02028649 2744938
8. Agnoli A, Fioravanti M, Lechner H. Efficacy of CDP-choline in chronic cerebral vascular diseases (CCVD), Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine In: Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. Novel biochemical, pharmacological clinical aspects of cytidinediphosphocholine, New York: Elsevier, 1985; 305-8.
9. Boismare F, le Poncin M, Lefrancois J, Lecordier JC Action of cytidinediphosphocholine on functional and hemodynamie effects of cerebral ischemia in cats. Pharmacology 1978; 17: 15-24. 684070
10. Cacabelos R, Caamano J, Gomez MJ, Fernandez-Novoa L, Franco-Maside A, Alvarez XA. Therapeutic effects of CDP-choline in Alzheimer disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci 1996; 777: 399-403. 8624120
11. Kakihana M, Fukuda N, Suno M, Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke 1988; 19: 217-22. 3344538
12. Serra I, Alberghina M, Viola M, Mistretta A, Giuffrida AM. Effect of CDP-choline on the biosynthesis of nucleic acids and proteins in brain regions during hypoxia. Neurochem Res 1981; 6: 607-18. 10.1007/ BF00963878 6168928
13. Zappia V, Kennedy P, Nilsson BI, Galletti P. Novel biochemical, pharmacological and clinical aspects of cytidinediphosphocholine. New York: Elsevier 1985
14. Maffei L, Fiorentini A. Electroretinographic responses to alternating gratings before and after section of the optic nerve. Science 1981; 211: 953-5. 7466369
15. Parisi V. Neural conduction in the visual pathways in ocular hypertension and glaucoma. Graefes Arch Clin Exp Ophthalmol 1997; 235: 136-46. 10.1007/BF00941720 9085108
16. Parisi V. Impaired visual function in glaucoma. Clin Neurophysiol 2001; 112: 351-8. 10.1016/S1388-2457(00)00525-3 11165541
17. Parisi V, Manni G, Centofanti M, Gandolfi SA, Olzi D, Bucci MG. Correlation between optical coherence tomography, pattern electroretinogram, and visual evoked potentials in open-angle glaucoma patients. Ophthalmology 2001; 108: 905-12. 10.1016/S0161-6420(00)00644-8 11320021
18. Celesia GG, Kaufman D, Cone SB. Simultaneous recording of pattern electroretinography and visual evoked potentials in multiple sclerosis. A method to separate demyelination from axonal damage to the optic nerve. Arch Neurol 1986; 43: 1247-52. 3778259
19. Chaturvedi N, Hedley-Whyte T, Dreyer EB. Lateral geniculate nucleus in Glaucoma. Am J Ophthalmol 1993; 116: 182-8. 8352303
20. Weber AJ, Chen H, Hubbard WC, Kaufman PL. Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest Ophthalmol Vis Sci 2000; 4: 1370-9.
21. Yucel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layerd of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol 2000; 118: 378-84. 10721961
22. Gupta N, Yucel YH. Brain changes in glaucoma. Eur J Ophthalmol 2003; suppl 3: S32-35
23. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 2003; 22: 465-81. 10.1016/S1350-9462(03)00026-0 12742392
24. Parisi V, Manni GL, Colacino G, Bucci MG. Cytidine-5′-diphosphocholine (Citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999; 106: 1126-34. 10.1016/S0161-6420(99)90269-5 10366081
25. Jasper HH. The ten-twenty electrode system of the international federation of electroencephalography. Clin Neurophysiol 1958; 10: 371-5.
26. Hawlina M, Konec B. New non-corneal HK-loop electrode for clinical electroretinography. Doc Ophthalmol 1992; 81: 253-9. 10.1007/BF00156014 1468355
27. Porciatti V, Falsini B. Inner retina contribution to the flicker electroretinogram: A comparison with the pattern electroretinogram. Clin Vis Sci 1993; 8: 435-47.
28. Fiorentini A, Maffei L, Pirchio M, Spinelli D, Porciatti V. The ERG in response to alternating gratings in patients with diseases of the peripheral visual pathway. Invest Ophthalmol Vis Sci 1981; 21: 490-3. 7275535
29. Porciatti V, Ventura LM. Normative data for a user-friendly paradigm for pattern electroretinogram recording. Ophthalmology 2004; 111: 161-8. 10.1016/j.ophtha.2003.04.007 14711729
30. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. Semin Ophthalmol 2003; 18: 50-7. 14566623
31. Stroux A, Korth M, Junemann A, Jonas JB, Horn F, Ziegler A, Martus P. A statistical model for the evaluation of sensory tests in glaucoma, depending on optic disc damage. Invest Ophthalmol Vis Sci 2003; 44: 2879-84. 10.1167/iovs.02-0419 12824226
32. Bayer UA, Maag KP, Erb C. Detection of optic neuropathy in glaucomatous eyes with normal standard visual fields using a test battery of short-wavelength automated perimetry and pattern electroretinography. Ophthalmology 2002; 109: 1350-61. 10.1016/S0161-6420(02)01100-4 12093662
33. Garway-Heath DF, Holder GE, Fitzke FW, Hitchings RA. Relationship between electrophysiological, psychophysical, and anatomical measurements in glaucoma. Invest Ophthalmol Vis Sci 2002; 43: 2213-20. 12091419
34. Bach M. Electrophysiological approaches for early detection of glaucoma. Eur J Ophthalmol 2001; 11(Suppl 2): S41-49. 11592530
35. Drasdo N, Aldebasi YH, Chiti Z, Mortlock KE, Morgan JE, North RV. The s-cone PHNR and pattern ERG in primary open angle glaucoma. Invest Ophthalmol Vis Sci 2001; 42: 1266-72. 11328738
36. Maddess T, James AC, Goldberg I, Wine S, Dobinson J. Comparing a parallel PERG, automated perimetry, and frequency-doubling thresholds. Invest Ophthalmol Vis Sci 2000; 41: 3827-32. 11053282
37. Parisi V, Colacino G, Milazzo G, Scuderi AC, Manni G. Effects of nicergoline on the retinal and cortical electrophysiological responses in glaucoma patients: A preliminary open study. Pharmacol Res 1999; 40: 249-55. 10.1006/phrs.1999.0507 10479469
38. Salgarello T, Colotto A, Falsini B, Buzzonetti L, Cesari L, Iarossi G, Scullica L. Correlation of pattern electroretinogram with optic disc cup shape in ocular hypertension. Invest Ophthalmol Vis Sci 1999; 40: 1989-97. 10440253
39. Parisi V, Pernini C, Guinetti C, Neuschuler R, Bucci MG. Electrophysiological assessment of visual pathways in glaucoma. Eur J Ophthalmol 1997; 7: 229-35. 9352275
40. Porciatti V, di Bartolo E, Nardi N, Fiorentini A. Responses to chromatic and luminance contrast in glaucoma: A psychophysical and electrophysiological study. Vision Res 1997; 37: 1975-87. 10.1016/ S0042-6989(97)00018-7 9274782
41. Pfeiffer N, Tillmon B, Bach M. Predictive value of the pattern electroretinogram in high-risk ocular hypertension. Invest Ophthalmol Vis Sci 1993; 34: 1710-5. 8473110
42. Rejdak R, Toczolowski J, Kurkowski J, Kaminski ML, Rejdak K, Stelmasiak Z, Grieb P. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit 2003; 9: PI24-28 12640353
43. Horn FK, Jonas JB, Budde WM, Junemann AM, Mardin CY, Korth M, Monitoring glaucoma progression with visual evoked potentials of the blue-sensitive pathway. Invest Ophthalmol Vis Sci 2002; 43: 1828-34. 12036986
44. Parisi V. Electrophysiological evaluation of the macular cone adaptation: VEP after photostress A review. Doc Ophthalmol 2001; 102: 251-62. 10.1023/A:1017514616801 11556488
45. Martus P, Junemann A, Wisse M, Budde WM, Horn F, Korth M, Jonas JB. Multivariate approach for quantification of morphologic and functional damage in glaucoma. Invest Ophthalmol Vis Sci 2000: 41: 1099-110. 10752947
46. Horn FK, Bergua A, Junemann A, Korth M. Visual evoked potentials under luminance contrast and color contrast stimulation in glaucoma diagnosis. J Glaucoma. 2000; 9: 428-37. 11131748
47. Greenstein VC, Seliger S, Zemon V, Ritch R. Visual evoked potential assessment of the effects of glaucoma on visual subsystems. Vision Res 1998; 38: 1901-11. 10.1016/S0042-6989(97)00348-9 9797966
48. Korth M, Nguyen NX, Junemann A, Martus P, Jonas JB. VEP test of the blue-sensitive pathway in glaucoma. Invest Ophthalmol Vis Sci 1994; 35: 2599-610. 8163348
49. Parisi V, Bucci MG. Visual evoked potentials after photostress in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 1992; 33: 436-42. 1740376
50. Goracci G, Francescangeli E, Mozzi R, Porcellati S, Porcellati G. Regulation of phospholipid metabolism by nucleotides in brain and transport of CDP-choline into brain, Novel Biochemical, Pharmacological and clinical aspects o cytidinediphosphocholine. In: Zappia V, Kennedy EP, Nilsson BI, Galletti P, eds. Novel Biochemical, Pharmacological and clinical aspects of cytidinediphosphocholine, New York: Elsevier, 1985; 105-9.
51. Kennedy EP. Biosynteis of phospholipids. Fed Proc 1957; 16: 847-53. 13480372 Fed Proc 1957; 16: 847-53. 13480372
52. Secades JJ, Frontera G. CDP-choline: Pharmacological and clinical review. Meth Find Exp Clin Pharmacol 1995; 17: 2-54.
53. Weiss GB. Metabolism and action of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995; 56: 637-60. 10.1016/0024-3205(94)00427-T 7869846
54. Quigley HA, Sanchez RM, Dunkelberger GR, L'Hernault NL, Baginski TA. Chronic glaucoma selectively damages large optic nerve fibers. Invest Ophthalmol Vis Sci 1987; 28: 913-20. 3583630
55. Quigley HA, Dunkelberger GR, Green WR. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers. Ophthalmology 1988; 95: 357-63. 3174003
56. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal Ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 1995; 36: 774-86. 7706025
57. Orzalesi N, Miglior S, Lonati C, Rosetti L. Microperimetry of localized retinal nerve fiber layer defects. Vision Res 1998; 38: 763-71. 10.1016/ S0042-6989(97)00171-5 9604104
58. Shuman JS, Hee MR, Puliafito CA, Wong C, Pedut-Kloizman T, Lin CP, Hertzmark E, Izatt JA, Swanson A, Fujimoto JG. Quantification of nerve layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol 1995; 113: 586-96. 7748128
59. Yucel YH, Gupta N, Kalichman MW, Mizisin AP, Hare W, Souza Lima Mde, Zangwill L, Weinreb RN. Relationship of optic disc topography to optic nerve fiber number in glaucoma. Arch Ophthalmol 1998; 116: 493-7. 9565048
60. Falsini B, Colotto A, Porciatti V, Buzzonetti L, Coppè A, de Luca LA. Macular flicker-and pattern ERGs are differently affected in ocular hypertension and glaucoma. Clin Vision Sci 1991; 6: 422-9.
61. Holopigian K, Sieple W, Mayron C, Koty R, Lorenzo M. Electrophysiological and psychophysical flicker sensitivity in patients with primary open angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 1990; 31: 1863-9. 2211032
62. Holopigian K, Seiple W, Greenstein VC. Electrophysiological evidence for outer retinal deficits in primary open angle glaucoma. Invest Ophthalmol Vis Sci 1993; 34: (Supp): 1269.
63. Gottlob I, Weghaupt H, Vass C, Auff E. Effect of levodopa on the human electroretinograrn and pattern visual evoked potentials Graefe's. Arch Clin Exp Ophthalmol 1989; 227: 421-7. 10.1007/BF02172892
64. Campos EC, Schiavi C, Benedetti P, Bolzani R, Porciatti V. Effect of citicoline on visual acuity in amblyopia: Preliminary results Graefe's. Arch Clin Exp Ophthalmol 1995; 233: 307-12.
65. Campos EC. Future directions in the treatment of amblyopia. The Lancet 1997; 149: 1190. 10.1016/S0140-6736(05)62410-5
66. Porciatti V, Schiavi C, Benedetti P, Baldi A, Campos EC. Cytidine-5′-diphosphocholine improves visual activity, contrast sensitivity and visually evoked potentials of amblyopic subjects. Curr Eye Res 1998; 17: 141-8. 10.1076/ceyr.17.2.141.5606 9523091
67. Gottlob I, Stangler-Zuschrott E. Effect of levodopa on contrast sensitivity and scotomas in human amblyopia. Invest Ophthatmol Vis Sci 1990; 31: 766-80.
68. Leguire LE, Rogers GL, Brener DL, Walson PD, Mc Gregor ML. Levodopa/ carbodopa for childhood amblyopia. Invest Ophthatmol Vis Sci 1993; 34: 3090-5.
69. Gottlob I. Charlier J. Reinecke RD. Visual acuities and scotomas after one week levodopa administration in human amblyopia. Invest Ophthalmol Vis Sci 1992; 33: 2722-8. 1639618
70. Agnoli A, Ruggieri S, Denaro A, Bruno G. New strategies in the management of Parkinson's disease: A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982; 8: 289-96. 7162583
71. Birbamer G, Gesterbrand E, Rainer J, Eberhardt R. CDP-choline in the treatment of Parkinson's disease. New Trends Clin Pharmacol 1990; 4: 1-6.
72. Manaka S, Fuchinoue T, Sakino H, Sano K. Mechanism of action of CDP-choline in Parkinsonism. Brain Nerve 1971; 24: 1051-66.
73. Virno M, Pecori-Giraldi J, Liguori A, de Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand Suppl 2000; 232: 56-7. 11235540